Retlirafusp Alfa Injection Plus Chemotherapy Versus Investigator's Choice of Anti-PD-1 Antibody Plus Chemotherapy as First-line Treatment for Advanced Gastric Cancer With Liver Metastases

NCT07677293 · clinicaltrials.gov ↗

PHASE3

Phase

NOT_YET_RECRUITING

Status

332

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Retlirafusp alfa Injection
DRUG: Capecitabine
DRUG: Oxaliplatin
DRUG: Sintilimab or Tislelizumab (based on investigator's choice)
DRUG: Capecitabine
DRUG: Oxaliplatin

Sponsor

Peking University